CoChat

Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Purpose To evaluate the outcomes of patients with chronic ocular inflammatory disease treated with mycophenolate mofetil as an immunosuppressive and steroid-sparing agent.Design Retrospective noncomparative interventional case series.Participants All patients with ocular inflammatory disease treated with mycophenolate mofetil at a single institution between 1998 and 2001.Methods Charts of patients seen on the Ocular Immunology and Uveitis Service at the Massachusetts Eye and Ear Infirmary were reviewed. Patients with chronic ocular inflammatory disease were included in the study.Main outcome measures Control of inflammation, steroid-sparing effect, visual acuity, and adverse reactions were measured.Results A total of 54 patients were evaluated. Control of ocular inflammation with mycophenolate mofetil as monotherapy was achieved in 35 patients (65%) and in 67 eyes (62%), and a steroid-sparing effect was achieved in 29 (54%) patients. Visual acuity was maintained or improved in 51 patients (94%) and in 97 eyes (90%). Side effects requiring discontinuation of medication occurred in 10 patients (18%). There was neither long-term morbidity nor mortality due to mycophenolate mofetil.Conclusions Mycophenolate mofetil is effective in the treatment of patients with steroid-dependent or -resistant chronic ocular inflammatory disorders that fail to respond to conventional steroid treatment. It is a safe and effective steroid-sparing immunomodulatory agent and can be considered an important addition to our armamentarium in the care of patients with ocular inflammatory disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0161-6420(03)00092-7

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 12 references

Cited by

See all 141

Metadata

Authors
Baltatzis, S., Tufail, F., Yu, E. N., Vredeveld, C. M., & Foster, C. S.
Affiliations
Massachusetts Eye and Ear Infirmary (US)
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2003-05
Volume
110
Issue
5
Pages
1061-1065
ISSN
0161-6420 (ISSN-L)
OpenAlex
W2012806608
Cited by
141
References
12
Citations by year
2024: 5 · 2023: 1 · 2022: 5 · 2021: 1 · 2020: 7 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 10 · 2015: 4 · 2014: 9 · 2013: 5 · 2012: 12
FWCI
10.30
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
mycophenolate mofetil, uveitis, steroid-sparing therapy, immunosuppressive therapy, immunomodulators, visual acuity outcomes, adverse drug reactions
MeSH terms
Adolescent, Adult, Chronic Disease, Female, Humans, Immunosuppressive Agents, IMP Dehydrogenase, Inflammation, Male, Middle Aged, Mycophenolic Acid, Endophthalmitis, Retrospective Studies, Visual Acuity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. https://app.cochat.ai/papers/10.1016/s0161-6420(03)00092-7
The paper
Baltatzis, S., Tufail, F., Yu, E. N., Vredeveld, C. M., & Foster, C. S. (2003). Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. https://doi.org/10.1016/s0161-6420(03)00092-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.